Work

703 POSTER A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor

Year: 2007

Type: conference-abstract

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(07)70502-5

Authors: R. Plummer, L. Vidal, R. Perrett, J. Spicer, P. Stopfer, M. Shahidi, G. Temple, A. Futreal, H. Calvert, J. de Bono

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2033363706

Cites:

Cited by: 6

Related to: 10